TU Delft and Imperial-founded genetic data analytics software provider BlueBee has been picked up after raising at least $13.5m of funding.

The Alphabet-backed smart vending operator is set to close down in the next two weeks having been valued at $100m in its last round.

Chalmers Ventures portfolio company Biofrigas has set out plans for a $1.7m IPO but has already issued around $1.2m to existing connections.

Novartis and Eli Lilly are set to score exits from the cancer and blood disease drug developer in an initial public offering set to raise up to $212m.

The move came after the digital health technology provider, which has a raft of corporate investors, reportedly failed to raise a nine-figure round last year.

The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.

Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

The Relx-backed big data analyser is reportedly lining up a confidential IPO filing in the coming weeks having previously raised $1.9bn in equity funding.

Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.

AstraZeneca and Fresenius Medical Care will exit the kidney disease treatment developer in a $725m acquisition that could potentially rise to $2.1bn.